Cultivating innovation post acquisition: Bayer and Vividion’s arm’s length model

When Vividion examined the next steps for their company, an IPO was the path forward. Until one day, Bayer called and plans changed. What has happened since then and how have the two companies worked to foster innovation and collaboration? Join Dr. Marianne De Backer, Chief Business Officer, for the Pharmaceuticals division of Bayer and Jeff Hatfield, CEO, Vividion, for a candid discussion about the arm’s length model, innovation, and advancements in the undruggable space.